Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469398 | 1.00 | RAB9A (0.41) | RAB9ASMN1; SMN2MAPTALDH1A1OPRK1 | |
| SCHEMBL5321509 | 0.88 | SMN1; SMN2 (0.42) | RAB9ASMN1; SMN2MAPTOPRK1NPC1 | |
| SCHEMBL5321515 | 0.88 | SMN1; SMN2 (0.42) | RAB9ASMN1; SMN2MAPTOPRK1NPC1 | |
| SCHEMBL5468309 | 0.83 | CNR1 (0.41) | SMN1; SMN2MAPTALDH1A1OPRK1HPGD | |
| SCHEMBL5321750 | 0.83 | OPRK1 (0.49) | SMN1; SMN2MAPTALDH1A1OPRK1LMNA | |
| SCHEMBL5321756 | 0.83 | OPRK1 (0.49) | SMN1; SMN2MAPTALDH1A1OPRK1LMNA | |
| SCHEMBL5468542 | 0.82 | ROCK2 (0.35) | ALDH1A1OPRK1LMNAKMT2ABTK | |
| SCHEMBL5322852 | 0.82 | ROCK2 (0.35) | ALDH1A1OPRK1LMNAKMT2ABTK | |
| SCHEMBL5468546 | 0.82 | ROCK2 (0.35) | ALDH1A1OPRK1LMNAKMT2ABTK | |
| SCHEMBL5475241 | 0.72 | PER2 (0.38) | BTKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007103719-A2 | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208001-A1 | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208001-A1 | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | HSD11B1, HSD17B1, HSD3B1 | RAB9A 3495/4885SMN1; SMN2 2875/4885MAPT 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.